Table 2

Characteristics of 107 patients in the I/O analysis

All (n=107)Deleterious DDR (n=19)Wild type/VUS DDR (n=88)
Age at start of treatment (years), median (range)61 (40–81)60 (40–74)61 (44–81)
Gender (male)78 (73%)13 (68%)65 (74%)
Nephrectomy100 (93%)18 (95%)82 (93%)
IMDC risk score at starting I/O therapy
 Favorable23 (21%)2 (11%)21 (24%)
 Intermediate65 (61%)15 (78%)50 (57%)
 Poor19 (18%)2 (11%)17 (19%)
I/O therapy type
 Anti-PD-1 monotherapy61 (57%)10 (53%)51 (58%)
 Anti-PD-L1 monotherapy12 (11%)3 (16%)9 (10%)
 Anti-PD-1+anti-CTLA-432 (30%)5 (26%)27 (31%)
 Anti-PD-1+anti-PD-L12 (2%)1 (5%)1 (1%)
I/O therapy category
 Monotherapy73 (68%)13 (68%)60 (68%)
 Combination34 (32%)6 (32%)28 (32%)
Line of I/O therapy
 First line40 (37%)8 (42%)32 (36%)
 ≥Second line67 (63%)11 (58%)56 (64%)
  • CTLA-4, cytotoxic T-lymphocyte-associated protein-4; DDR, DNA damage repair; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; I/O, immune-oncology; PD-1, programmed cell death-1; PD-L1, programmed cell death-ligand 1; VUS, variants of unknown significance.